GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission. Blenrep (belantamab mafodotin) becomes the first ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it failed a confirmatory ...

GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus ...

Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collection targets using its ...

Harvey Jones has been hunting for the best shares to buy for his SIPP, and found what he thinks is one in a surprising place.

GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...

Melbourne man Ralph Markham’s life was transformed by love and, later, a devastating cancer diagnosis. Now, he is hoping new therapies will give him more time with his wife Cathy and their blended ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

(GLOBE NEWSWIRE) -- "Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there's no clear, consistent guidance -- ask five academic physicians and you'll get five different ...

GSK plc will present new data from its haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (6 - 9 December), reinforcing its potential to redefine ...